I agree that this site is using cookies. You can find further informations here.
X
Cappuzzo, F. (Federico)
218  results:
Search for persons X
?
1

Low risk of hyperprogression with first-line chemoimmunothe..:

Li, L.X. (Lee X.) ; Cappuzzo, F. (Federico) ; Matos, I. (Ignacio)...
https://hdl.handle.net/10171/66059.  , 2023
Link: https://hdl.handle.net/1..
 
?
2

Exposure–response relationship for ramucirumab from the ran..:

Smit, Egbert F. ; Garon, Edward B. ; Reck, Martin...
Cancer Chemotherapy and Pharmacology.  82 (2018)  1 - p. 77-86 , 2018
Link: https://doi.org/10.1007/..
 
?
3

First-Line Crizotinib versus Chemotherapy in ALK-Positive L..:

Solomon, Benjamin J ; Mok, Tony ; Kim, Dong-Wan...
New England Journal of Medicine, Vol.371 No.23, pp.2167-2177.  , 2014
Link: http://hdl.handle.net/10..
 
?
4

Identifying and Targeting ROS1 Gene Fusions in Non-Small Ce..:

Davies, Kurtis D ; Le, Anh T ; Theodoro, Mariana F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703205.  , 2012
Link: http://www.ncbi.nlm.nih...
 
?
5

Rachel score: a nomogram model for predicting the prognosis..:

La Salvia, A. ; Marcozzi, B. ; Manai, C....
Journal of Endocrinological Investigation.  , 2024
Link: https://doi.org/10.1007/..
 
?
6

244MO Primary results from IMscin002: A study to evaluate p..:

Cappuzzo, F. ; Zvirbule, Z. ; Korbenfeld, E.P....
ESMO Open.  9 (2024)  - p. 102706 , 2024
Link: https://doi.org/10.1016/..
 
?
7

KontRASt-02: A Phase III Trial Investigating the Efficacy a..:

Cappuzzo, F. ; Castro Junior, G. ; Kang, J.H....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  1 - p. e14 , 2024
Link: https://doi.org/10.1016/..
 
?
8

Amivantamab plus chemotherapy with and without lazertinib i..:

Passaro, A. ; Wang, J. ; Wang, Y....
Annals of Oncology.  35 (2024)  1 - p. 77-90 , 2024
Link: https://doi.org/10.1016/..
 
?
9

104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + ant..:

Paz-Ares, L. ; Cappuzzo, F. ; Yamamoto, N....
ESMO Open.  9 (2024)  - p. 102683 , 2024
Link: https://doi.org/10.1016/..
 
?
10

60P Sacituzumab govitecan (SG) + pembrolizumab (pembro) in ..:

Cappuzzo, F. ; Patel, J. ; Cho, B.C....
ESMO Open.  9 (2024)  - p. 102639 , 2024
Link: https://doi.org/10.1016/..
 
?
11

53P MET exon 14 skipping mutations in non-small cell lung c..:

Reale, M.L. ; Passiglia, F. ; Cappuzzo, F....
ESMO Open.  9 (2024)  - p. 102632 , 2024
Link: https://doi.org/10.1016/..
 
?
12

3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-m..:

Gentzler, R.D. ; Spira, A. ; Melosky, B....
ESMO Open.  9 (2024)  - p. 102582 , 2024
Link: https://doi.org/10.1016/..
 
?
13

70MO Genomic profiling to expand precision cancer medicine ..:

Botticelli, A. ; Scagnoli, S. ; Conte, P.F....
ESMO Open.  8 (2023)  1 - p. 100928 , 2023
Link: https://doi.org/10.1016/..
 
?
14

P2.05-02 MAPK1/MAPK3 Mutations Enhance Immunotherapy Effica..:

Cappuzzo, F. ; Fusco, F. ; Bonanno, L....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S307 , 2023
Link: https://doi.org/10.1016/..
 
?
15

Randomized open-label controlled study of cancer vaccine OS..:

Besse, B. ; Felip, E. ; Garcia Campelo, R....
Annals of Oncology.  34 (2023)  10 - p. 920-933 , 2023
Link: https://doi.org/10.1016/..
 
1-15